The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurological Disorder Drugs Market Research Report 2024
Synopsis
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
The global Neurological Disorder Drugs market was valued at US$ 1961.4 million in 2023 and is anticipated to reach US$ 3515.4 million by 2030, witnessing a CAGR of 8.7% during the forecast period 2024-2030.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
This report aims to provide a comprehensive presentation of the global market for Neurological Disorder Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Disorder Drugs.
Report Scope
The Neurological Disorder Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurological Disorder Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurological Disorder Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Segment by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurological Disorder Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
The global Neurological Disorder Drugs market was valued at US$ 1961.4 million in 2023 and is anticipated to reach US$ 3515.4 million by 2030, witnessing a CAGR of 8.7% during the forecast period 2024-2030.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
This report aims to provide a comprehensive presentation of the global market for Neurological Disorder Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Disorder Drugs.
Report Scope
The Neurological Disorder Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurological Disorder Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurological Disorder Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Segment by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurological Disorder Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antipsychotic
1.2.3 Hypnotic & Sedative
1.2.4 Analgesics
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurological Disorder Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurological Disorder Drugs Market Perspective (2019-2030)
2.2 Neurological Disorder Drugs Growth Trends by Region
2.2.1 Global Neurological Disorder Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurological Disorder Drugs Historic Market Size by Region (2019-2024)
2.2.3 Neurological Disorder Drugs Forecasted Market Size by Region (2025-2030)
2.3 Neurological Disorder Drugs Market Dynamics
2.3.1 Neurological Disorder Drugs Industry Trends
2.3.2 Neurological Disorder Drugs Market Drivers
2.3.3 Neurological Disorder Drugs Market Challenges
2.3.4 Neurological Disorder Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurological Disorder Drugs Players by Revenue
3.1.1 Global Top Neurological Disorder Drugs Players by Revenue (2019-2024)
3.1.2 Global Neurological Disorder Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurological Disorder Drugs Revenue
3.4 Global Neurological Disorder Drugs Market Concentration Ratio
3.4.1 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2023
3.5 Neurological Disorder Drugs Key Players Head office and Area Served
3.6 Key Players Neurological Disorder Drugs Product Solution and Service
3.7 Date of Enter into Neurological Disorder Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurological Disorder Drugs Breakdown Data by Type
4.1 Global Neurological Disorder Drugs Historic Market Size by Type (2019-2024)
4.2 Global Neurological Disorder Drugs Forecasted Market Size by Type (2025-2030)
5 Neurological Disorder Drugs Breakdown Data by Application
5.1 Global Neurological Disorder Drugs Historic Market Size by Application (2019-2024)
5.2 Global Neurological Disorder Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurological Disorder Drugs Market Size (2019-2030)
6.2 North America Neurological Disorder Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurological Disorder Drugs Market Size by Country (2019-2024)
6.4 North America Neurological Disorder Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurological Disorder Drugs Market Size (2019-2030)
7.2 Europe Neurological Disorder Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurological Disorder Drugs Market Size by Country (2019-2024)
7.4 Europe Neurological Disorder Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurological Disorder Drugs Market Size (2019-2030)
8.2 Asia-Pacific Neurological Disorder Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurological Disorder Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurological Disorder Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurological Disorder Drugs Market Size (2019-2030)
9.2 Latin America Neurological Disorder Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurological Disorder Drugs Market Size by Country (2019-2024)
9.4 Latin America Neurological Disorder Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurological Disorder Drugs Market Size (2019-2030)
10.2 Middle East & Africa Neurological Disorder Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurological Disorder Drugs Introduction
11.1.4 Novartis Revenue in Neurological Disorder Drugs Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Neurological Disorder Drugs Introduction
11.2.4 GlaxoSmithKline Revenue in Neurological Disorder Drugs Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Merck & Co.
11.3.1 Merck & Co. Company Detail
11.3.2 Merck & Co. Business Overview
11.3.3 Merck & Co. Neurological Disorder Drugs Introduction
11.3.4 Merck & Co. Revenue in Neurological Disorder Drugs Business (2019-2024)
11.3.5 Merck & Co. Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Neurological Disorder Drugs Introduction
11.4.4 Bayer Revenue in Neurological Disorder Drugs Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Neurological Disorder Drugs Introduction
11.5.4 AstraZeneca Revenue in Neurological Disorder Drugs Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Neurological Disorder Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Neurological Disorder Drugs Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Detail
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Introduction
11.7.4 Teva Pharmaceutical Revenue in Neurological Disorder Drugs Business (2019-2024)
11.7.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
